Nanobiotix S.A.
$38.40▼ 2.74%($-1.08)
TickerSpark Score
59/100
▌ Mixed
20
Valuation
60
Profitability
100
Growth
56
Health
60
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NBTX research report →
52-Week Range64% of range
Low
$4.79
Current
$38.40
High
$57.14
Company Overviewwww.nanobiotix.com
About the company
Nanobiotix S. A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer.
- CEO
- Laurent Levy
- IPO
- 2020
- Employees
- 108
- HQ
- Paris, FR
Price Chart
+711.84% · this period
Valuation
- Market Cap
- $1.94B
- P/E
- -68.43
- P/S
- 59.79
- P/B
- -19.59
- EV/EBITDA
- -150.40
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -36.49%
- Net Margin
- -80.83%
- ROE
- 31.23%
- ROIC
- -74.29%
Growth & Income
- Revenue
- $29.64M · 512.28%
- Net Income
- $-23,961,000 · 64.83%
- EPS
- $-0.50 · 65.28%
- Op Income
- $-10,818,000
- FCF YoY
- -66.53%
Performance & Tape
- 52W High
- $57.14
- 52W Low
- $4.79
- 50D MA
- $38.75
- 200D MA
- $27.72
- Beta
- 0.59
- Avg Volume
- 79.41K
Get TickerSpark's AI analysis on NBTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Coverage · NBTX
Our NBTX coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on NBTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NBTX report →Internal Compare
Similar companies
Peers in the same neighborhood.